Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

NCT01132989 is registered in ClinicalTrials.gov with Florida Academic Dermatology Centers as lead sponsor.

NCT NCT01132989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01132989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Lead sponsor
Florida Academic Dermatology Centers
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2010
Completion date
December 31, 2010
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma